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In viva imaging of inflammation using an aptamer inhibitor of 
human neutrophil elastase 
Josephine Charlton, Joseph Sennello and Drew Smith 
Background: We previously reported the isolation of aptamer irreversible 
inhibitors of human neutrophil elastase. We now report on the application of 
aptamer technology to the field of diagnostic imaging. 
Results: The enzyme elastase has been reported to bind to the surface of 
activated neutrophils. Using a fluorescent flow cytometry assay, we showed that 
an aptamer inhibitor of elastase also binds preferentially to activated 
neutrophils. We then tested the ability of the aptamer to image inflammation in 
viva in a rat reverse passive Arthus reaction model. The aptamer achieved a 
peak target-to-background (T/B) ratio of 4.3 * 0.6 in 2 hours. IgG, which is 
used clinically to image inflammation, took a longer time to achieve a lower T/B: 
3.1 + 0.1 at 3 hours. The difference in T/B values is due to the faster clearance 
of the aptamer signal from the blood pool. 
Conclusions: It is feasible to apply aptamer ligands for use in diagnostic 
imaging, where they may offer significant advantages over monoclonal 
antibodies and other reagents. 
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Introduction 
The development of SELEX technology has enabled the 
generation of nucleic acid ligands, known as aptamers, to a 
wide variety of target molecules [l,Z]. These ligands are 
comparable to monoclonal antibodies in respect to their 
affinity and specificity, thus suggesting their possible use 
in therapeutic and diagnostic applications [3-51. A particu- 
lar application for which aptamers might be well suited is 
diagnostic imaging. Antibodies are large molecules 
(-180 kDa), and are cleared very slowly from circulation. 
As a result, they access some biological compartments and 
targets slowly, or not at all; when they do bind their 
targets, their slow clearance may necessitate waiting for 
days before a significant signal emerges from the back- 
ground of excess unbound ligand. Not only is this long 
waiting period inconvenient, it limits the usefulness of 
imaging technology in diagnosing acute conditions, and 
precludes the use of short-lived radionuclides. In contrast, 
aptamers are much smaller (-10 kDa) and, in the absence 
of stabilizing formulations, are cleared quickly from the 
circulation. These properties led us to test the utility of an 
aptamer in inflammation imaging. 
Infection and inflammation lead to the accumulation of 
neutrophils at the site of inflammation [6-81. There, a 
variety of stimuli cause the release of neutrophil granules 
into the extracellular space [9]. Among the contents of 
these granules is neutrophil elastase, a serine protease that 
can degrade a variety of proteins, including those of host 
connective tissue. Because of its potency, elastase activity 
is highly localized to the neutrophil vicinity by high 
concentrations of a-1 proteinase inhibitor (a-l PI) 
[lo-131. In addition, elastase activity has been reported to 
be stably bound to the neutrophil surface [14,15]. Thus, 
despite the fact that neutrophil elastase is a soluble 
protein, it appears to be sufficiently localized to be a plau- 
sible target in diagnostic imaging of inflammation. 
We have described the isolation and characterization of 
aptamers that are highly potent and specific irreversible 
inhibitors of neutrophil elastase [16,17]. We used a 
method known as ‘blended SELEX’, in which a small, 
weakly reactive reversible inhibitor of elastase (a valyl 
diphenyl ester phosphonate) was incorporated into a ran- 
domized nucleic acid library. This method endows the 
library with a chemical function that forms a covalent 
bond with the active-site serine of elastase. By using the 
SELEX process of iterative selection and amplification, 
the nucleic acid sequences that best promote the covalent 
reaction of the valyl phosphonate moiety with elastase 
were identified. These inhibitors inactivate elastase with 
rate constants of l-3 x 10s M-l min-l, nearly two orders of 
magnitude faster than peptide-based phosphonate 
inhibitors [16,18]. In addition to inhibiting elastase free in 
solution, we showed that these aptamers are highly effec- 
tive at blocking degradation of elastin particles by acti- 
vated neutrophils. Recently, we have also shown that our 
elastase aptamer reduces lung injury in a rat alveolitis 
model [19]. 
Here, we began our imaging studies by characterizing the 
interaction of the aptamers with neutrophils by fluorescence 
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An aptamer inhibitor of elastase (NX21909). 
The inhibitor is composed of two annealed 
DNA oligonucleotides. The ‘splint’ oligonu- 
cleotide (splint oligo) is modified at the 5’ end 
with the valyl phosphonate inhibitor of elas- 
C A 
F:& 
tase to form 571 sp:valP. The active-site serine 
NX21909 of elastase attacks the phosphorus atom, dis- 
placing a phenyl group to form a serine-phos- 
I 
phonate ester. The aptamer component of the 
Aptamer inhibitor is a DNA sequence whose selection 
is described in [I 61. This oligonucleotide was 5’ 
i 
aggacgat g 
I I I I I I I I I 
3’ 
tcctgctac 
Splint oligo 
Fluorescein Valyl phosphonate 
571sp:valP 
(via hexylamine linker 
and NHS ester intermediate) Chemistry & Biology 
modified for imaging experiments by addition 
of fluorescein, to produce NX21909F, or a 
peptide ‘cage’, to produce N21909N:Hil5, at 
its 5’ end. 
NX21909F 
(via hexylamine linker) 
flow cytometry. We found that the elastase inhibitor binds 
to activated neutrophils from both humans and rats, and 
that there is a linear correlation between elastase activity 
and fluorescence intensity. We tested imaging in viva in a 
rat model of the reverse passive Arthus reaction induced 
by immune complex deposition. Using region-of-interest 
(ROI) analysis, we found a target-to-background ratio of 
4.3 + 0.6 at 2 h after administration of the elastase 
aptamer, compared to a ratio of 3.1 f 0.1 at 3 h for IgG, 
which is used clinically as an inflammation imaging agent 
[20-Z]. These results indicate that aptamer ligands may 
be of value in diagnostic imaging. 
Results and discussion 
Flow cytometry analysis of neutrophil labeling 
The potential utility of elastase inhibitors as imaging 
agents was suggested to us by reports that elastase is 
bound to the surface of activated neutrophils. We first 
asked whether our aptamer inhibitor (Figure 1, NXZ1909) 
could specifically label activated neutrophils in vitro. Flow 
cytometry (FACS) was used to detect binding of a fluores- 
cently labeled aptamer (Figure 1, NX21909F) to human 
neutrophils. These experiments show that the elastase 
inhibitor aptamer does generate a strong fluorescence 
signal, relative to autofluorescence, on activated neu- 
trophils. Furthermore, the fluorescence intensity is 
strongly correlated with the level of elastase activity 
induced (Figure Z), consistent with the hypothesis that 
elastase is a binding target of the aptamer on the neu- 
trophil cell surface. Figure 2 also shows that there is a sig- 
nificant level of non-specific binding by a control DNA 
(30N7), and that immune complex activation induces 
somewhat higher cell binding relative to elastase activity 
than do other modes of activation. 
Binding of elastase and control oligonucleotides to 
activated live neutrophils is linear with respect to DNA 
concentration, and is not saturable in the range of concen- 
trations studied (Figure 3, circles). Some or all of this 
binding could be the result of endocytotic uptake of DNA 
[23]. We evaluated the possible contribution of such active 
mechanisms of DNA binding by determining binding to 
fixed cells (Figure 3, squares). Binding of both DNAs is 
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Correlation between elastase activity and neutrophil-labeling intensity. 
Human neutrophil preparations were activated by the indicated 
compounds, and assayed in parallel for elastase activity (x axis) and 
neutrophil binding (y axis). Closed circles, NX21909F; open circles, 
30N7 (the control pool of oligonucleotides that has 30 randomized 
nucleotides between the same 5’ and 3’ PCR primer binding sites as 
the parent library from which NX21909 was selected). Bars indicate 
standard errors of the mean for three determinations, line is a linear 
regression by least-squares analysis. R* (NX21909F) = 0.76, P< 0.05; 
R2 (30N7) = 0.44, P> 0.1. LPS, lipopolysaccharide; C5a, complement 
factor 5a; IC, immune complex; PMA, phorbol myristyl acetate; 
A231 87, calcium ionophore A231 87. 
Figure 3 Figure 4 
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DNA binding to live and fixed activated neutrophils. Neutrophils were 
activated with phorbol myristyl acetate (PMA) for 30 min at 37°C. One 
portion was fixed in 3% formaldehyde/0.25% glutaraldehyde/phosphate- 
buffered saline (PBS), while the unfixed portion was processed in parallel. 
DNAs were added at the indicated concentration to 2 x 1 O5 cells in 
0.4 ml Hank’s balanced saline solution (HBSS), and allowed to bind for 
30 min at 37°C. Theoretical lines are linear regressions for all but 
‘NX21909F fixed’, which was found to fit better to a hyperbolic curve 
(r-values 0.929 versus 0.909). 
reduced for fixed cells, and binding by NX21909 appears 
to plateau at concentrations > 5 x 10m7 M, suggesting that 
binding to the neutrophil cell surface is being saturated. 
Fixation has different effects on binding by the DNAs, 
reducing binding by 4.4-fold for the control, against 1.9- 
fold (below 5 x lOA M) for the elastase aptamer. This 
result is consistent with the hypothesis that the elastase 
aptamer binds to activated neutrophils by specific, as well 
as non-specific, mechanisms. 
We further characterized the nature of aptamer binding to 
neutrophils by adding denatured herring sperm DNA as a 
non-specific competitor (Figure 4). For both the elastase 
aptamer and the control oligonucleotide, binding to neu- 
trophils shows partial competition. We interpret these data 
in terms of three modes of binding: (1) A non-specific, sat- 
urable component. This component is represented by the 
portion of the curves between O-100 1.18 ml-l herring sperm 
DNA where binding is competed away in a dose-depen- 
dent fashion; (‘2) A non-specific, non-saturable component. 
This component is represented by the plateau regions of 
the curves, above 100 pg ml-l herring sperm DNA, and may 
result from active uptake of DNA into neutrophils [23]; (3) 
Specific binding to elastase. This is the binding by the elas- 
tase aptamer that cannot be competed by herring sperm 
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Competition for neutrophil labeling by non-specific DNA. Elastase 
aptamer (NX21909F) or randomized control (30N7) were at 30 nM, 
mixed with 1 O5 human neutrophils and 0.1 Fg ml-r PMA in 0.4 ml total 
volume. Sheared denatured herring sperm DNA was included at the 
indicated concentrations. The data are fitted to a theoretical curve for 
partial competitive inhibition, y= F,,(l + (P[I]/K,)I(l + [IIIKJ), where 
F,, is fluorescence in the absence of inhibitor, j3 is the fraction of 
uninhibited fluorescence remaining at infinite inhibitor concentration, 
and K, is the constant for half-maximal inhibition [36]. By this analysis, 
competitor DNA has a similar inhibition constant for both the elastase 
aptamer and the control (-10 ug ml-l). However, whereas 0.73 
(k 0.07) of the control DNA fluorescence can be competed away, only 
0.55 (rt 0.04) of the elastase aptamer fluorescence can be competed. 
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DNA, and is represented by the differences in the plateau 
levels of binding by the control and elastase oligonu- 
cleotides. Although these data are open to other mechanis- 
tic interpretations, the results are compatible with the 
conclusion that the elastase aptamer binds activated neu- 
trophils with a strong signal and some degree of specificity. 
We determined cell-binding specificity of aptamer by mea- 
suring binding to the peripheral blood mononuclear cell 
(PBMC) fraction alone and in the presence of neutrophils. 
PBMCs activated by phorbol myristyl acetate (PMA) are 
labeled by the elastase aptamer with an intensity 0.15 + 0.1 
times that of neutrophils, while the 30N7 control oligonu- 
cleotide labels PBMCs at 0.23 + 0.2 times the neutrophil 
intensity. This result is consistent with reports that 
PBMCs express low levels of elastase [24]. They do not 
significantly reduce the intensity of neutrophil labeling, 
however, when present at up to fivefold excess over neu- 
trophils (data not shown). We also evaluated the effects of 
plasma on neutrophil labeling. Plasma contains high levels 
of a-1 PI, which can compete with the elastase aptamer for 
free elastase in solution (data not shown), and so could 
block binding to neutrophils. Addition of plasma at up to 
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10% of volume does reduce labeling to about 60% of the 
intensity in the absence of plasma (not shown). This effect, 
however, does not appear to be due to competition from a- 
l PI, which can be added at 100-fold excess (1 PM concen- 
tration) over the elastase aptamer without reducing 
labeling intensity (data not shown). This result is consis- 
tent with that of Owen et al. [lS], who found that a-l PI 
was unable to inhibit surface-bound elastase. It is likely 
that the reduction of aptamer binding is due to degradation 
by plasma nucleases. 
As we intended to use rat as a model system, we also 
examined binding to rat neutrophils. The elastase 
inhibitor used in these studies inactivates partially puri- 
fied rat neutrophil elastase with a second-order rate con- 
stant of 1.1 x lo7 M-1 min-l [19]. This rate is about a third 
of that for the inactivation of human neutrophil elastase. 
As with human neutrophils, the elastase aptamer labels rat 
neutrophils in a dose- and activation-dependent fashion, 
but does so at an intensity only 0.2-0.5 that of human neu- 
trophils. This lesser intensity is consistent with the rela- 
tively low levels of elastase found in rat neutrophils [ZS]. 
To summarize, these in vitro experiments show that the 
elastase aptamer binds to activated neutrophils from both 
rats and humans, and only weakly to quiescent neutrophils 
or to lymphocytes. The intensity of the binding signal cor- 
relates with elastase activity, although there is a significant 
non-specific, non-saturable binding component. Binding 
can take place in the presence of plasma, albeit with a sig- 
nificant reduction in signal. On the basis of these findings, 
we thought it plausible that an imaging signal could be 
generated at an inflammatory locus in viva. 
In viva imaging 
We induced a reverse passive Arthus (RPA) reaction in 
rats as our inflammation model [26]. Deposits of immune 
complexes were formed by intradermal injection of rabbit 
anti-bovine serum albumin (BSA) IgG in one forelimb, 
followed by intravenous tail vein injection of BSA. This 
model was preferred because our in vitro work showed 
that immune complexes stimulated elastase release and 
led to neutrophil labeling (Figure Z), whereas other 
inflammatory stimuli such as bacterial lipopolysaccharide 
(LPS) and complement fragment C5a did not. Visual 
inspection of the RPA reaction site showed marked 
swelling and reddening of the skin beginning l-l.5 h 
post-injection, reaching a maximum at 3-3.5 h, which was 
sustained for 2 8 h. Histological analysis of skin sections at 
the site of the RPA reaction shows a large influx of neutro- 
phils (Figure 5). Control injections of saline in the oppo- 
site forelimb caused no swelling, nor was there any 
accumulation of neutrophils. 
99mTc is a gamma-emitting radionuclide that has a 6 h 
half-life and an energy emission spectrum which is ideal 
Fiaurn 5 
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Histological analysis of the reverse passive Arthus reaction. Skin 
samples were excised from the sites of injection of saline (a), or anti- 
BSA (b), fixed in formalin, embedded in paraffin, sectioned and stained 
with hematoxylin and eosin. Neutrophils are the darkly stained cells that 
infiltrate the tissues. Magnification is x 20. 
for imaging applications. Imaging agents were labeled 
with 99mT~ and given by intravenous injection 3.5-4 h 
after induction of inflammation. The agents were the 
elastase aptamer (NXZ1909), a negative control aptamer 
(NX303), and rat IgG as a positive control. Rats were 
imaged in 10 min frames continuously for 40 min under 
anesthesia, then returned to their cages. Additional 
10 min frames were taken every hour up to 4 h after 
administration of imaging agent. 
A comparison of the elastase aptamer with the control 
aptamer and IgG at 10, 30, 60 and 120 min is shown in 
Figure 6. IgG, as expected, displays increased intensity in 
the RPA forelimb compared with the saline control. Clear- 
ance from circulation is slow, leading to high background 
intensity in the peripheral tissues. The non-specific 
control aptamer NX303 displays increased intensity in the 
RPA forelimb relative to the saline control. This apparent 
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Figure 6 
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inflammation imaging by NX21909 and IgG. A time series is shown in 
which the left forelimb of each rat is the site of the RPA reaction, 
indicated by the arrow, and the right forelimb is the background control 
(saline injection). Images were captured on a 256 x 256 pixel matrix. 
Images were smoothed, and color intensities normalized to total counts 
in the frame: purple, > 3 x 1 O-6 of the total counts per pixel; green, 
> 3 x 1 Oe4 of the total counts per pixel; red, > 3 x 1 O-3 of the total 
counts per pixel; white, > 1 O-* of the total counts per pixel. 
binding may be due to increased blood flow, and to non- 
specific binding by neutrophils, as was shown in vitro. The 
elastase aptamer NX21909 shows greater intensity than 
the control oligonucleotide in the RPA forelimb, and per- 
sists in this forelimb longer than the control. In contrast to 
IgG, clearance from circulation is rapid, so that back- 
ground intensity in peripheral tissues is low. 
Target-to-background (T/B) ratios were determined by 
ROI analysis: the c.p.m. in the injection region (between 
the elbow and wrist) were quantified and expressed as the 
ratio of c.p.m. in the RPA site to those at the saline injec- 
tion site (Figure 7a). The T/B ratio of the IgG-positive 
control rises slowly to a level of -3 at 3-4 h. This result is 
quantitatively similar to results reported elsewhere [20,22]. 
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Quantification of imaging signal. (a) Target-to-background ratios were 
computed as the quotient of counts in the RPA forelimb to those in the 
saline forelimb. Bars indicate the s.e.m. For the elastase aptamer 
NX21909, n = 7; for the control oligo NX303, n = 5; for the positive 
control IgG, n = 3. For four rats each, NX21909 and NX303 were 
blinded and coded before injection, to eliminate bias from the ROI 
analysis. There was no significant difference in computed T/B between 
the four blind and three open experiments done with NX21909 
(P> 0.98 by paired f-test analysis), so both data sets were combined. 
The overall level of significance for the difference between the 
NX21909 and NX303 data sets is P= 0.023. For the difference 
between NX21909 and IgG, P< 0.01. (b) The percent injected dose 
was calculated from the counts in the ROI as a percent of counts in 
the whole rat at the initial time of 10 min, corrected for decay. 
The T/B ratio of the elastase aptamer (NX21909) rises 
much more quickly to a higher maximum of -4 at 2 h, 
then begins to decline. A significant signal is also shown 
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by the negative control aptamer (NX303), and the two 
aptamers are difficult to distinguish by inspection, espe- 
cially in the early portions of the time course. This result 
mirrors the non-specific binding to activated neutrophils in 
vitro (Figures 2,3,4). The T/B ratio of the elastase aptamer 
is significantly greater than in the negative control over the 
course of the experiment (P = 0.023 by paired t-test analy- 
sis). Although capillary leak or non-specific uptake of DNA 
probably contributes to the imaging signal, this difference 
indicates that elastase-binding activity makes a significant 
contribution as well. 
Analysis of the total c.p.m. at the inflammation site shows 
fundamental differences in the behavior of the elastase 
aptamer and IgG (Figure 7b). The initial levels of IgG and 
elastase aptamer in the RPA forelimb are similar, but IgG 
accumulates slowly over time, whereas the elastase 
aptamer decreases. The superior T/B ratios achieved by 
the elastase aptamer are due to its very rapid clearance 
from the non-inflamed forelimb. By contrast, there is little 
or no clearance of IgG from the non-inflamed forelimb. 
The results demonstrate the potential feasibility of using 
aptamers as reagents for diagnostic imaging. Like mono- 
clonal antibodies, aptamers bind tightly and specifically to 
target molecules. Monoclonal antibodies are handicapped 
as imaging agents by their slow clearance rate: the time 
required to achieve a significant T/B ratio is often several 
days [27,‘28]. Aptamers, being nucleic acids, are cleared 
quickly from circulation, resulting in low background 
levels and high T/B ratios. The particular formulation 
used in this study, unmodified and unprotected DNA, is 
cleared rapidly, and is also highly susceptible to plasma 
n&ease degradation. Specific targeting of an inflamma- 
tion site was still attained, despite minimal opportunities 
for the aptamer to interact with its target. It is likely that 
the use of more stable chemistries and formulations 
[29,30] will further optimize the imaging signal. 
Two critical issues involved in evaluating aptamers as 
imaging agents are the specificity of the signal and its 
intensity. Aptamer ligands generally display high speci- 
ficity [30-321, and the elastase aptamer has also shown 
high specificity in vitro [16]. We found a significant non- 
specific binding component in the cell-binding assay 
(Figures 3,4) and in RPA imaging (Figure 7). There have 
been several reports of DNA-binding activity by neu- 
trophils [23,33,34], which may account for the non-specific 
binding. Binding of DNA by the Mac-l protein, which is 
upregulated upon neutrophil activation, results in the 
internalization of DNA [23]. This type of binding may 
account for our observations that binding of NX21909 is 
only partly competed by herring sperm DNA. 
These non-specific mechanisms cannot account for all of 
the binding by the elastase inhibitor NX21909. Both in 
vitro and in viva, binding by NX21909 to the targeted cells 
or tissues is significantly greater than that to non-specific 
controls. The in vitro data (Figures 3,4) show that non-spe- 
cific binding by neutrophils cannot account for all of the 
binding by NX21909; the in viva data (Figure 7) show that 
neither this mechanism nor vascular leak can account for 
all of the imaging signal generated by NX21909. 
Although imaging, as measured by T/B ratio is twofold to 
threefold higher for NX21909 than for IgG at 120 min 
(Figure 7a), the absolute intensity of the signal is twofold 
to threefold lower (Figure 7b). One probable reason for 
the low signal intensity is the relatively low levels of elas- 
tase expressed by rat neutrophils relative to human neu- 
trophils [35]. Rat neutrophils instead express high levels 
of cathepsin G, which does not bind the elastase aptamer 
[19]. These low levels of elastase expression may not limit 
signal intensity in other animal models or in humans. 
Other factors that may limit signal intensity are the phar- 
macokinetic and biodistribution properties of the aptamer, 
which prevent it from accumulating in the target tissue. 
Inspection of imaging experiments indicates that much of 
the radioactivity is initially taken up by the liver, then 
excreted into the gut. Significant accumulation in the 
kidneys and bladder is also evident. This pattern of 
biodistribution could interfere with some inflammatory 
imaging applications, such as diagnosis and localization of 
inflammatory bowel disease. Further progress in the 
development of aptamer imaging technology will focus on 
finding more stable formulations. 
Significance 
An aptamer irreversible inhibitor of neutrophil elastase 
was successfully used for diagnostic imaging of inflam- 
mation in rats. The aptamer was compared with IgG, 
which is used clinically in diagnostic imaging of inflam- 
matory diseases. The aptamer achieved a significantly 
higher target-to-background ratio in less time than IgG. 
This ratio was achieved primarily by the rapid clearance 
of the aptamer from the peripheral circulation. Although 
preliminary, these results indicate that aptamer technol- 
ogy may be successfully applied to diagnostic imaging. 
Materials and methods 
Oligonucleotides 
The core elastase inhibitor NX21909 is diagrammed in Figure 1. The 
fluorescently labeled derivative of the inhibitor, NX21909F, has fluores- 
cein at the 5’ end of the aptamer moiety, and was synthesized and 
HPLC-purified by Operon. This derivative inactivates human neutrophil 
elastase (hNE) at the same rate as its parent (3 x 1 O7 M-1 mini), as 
determined by the progress curve method. The ligand for in viva 
imaging, designated NX21909N, was first synthesized as the 5’hexy- 
lamine derivative of NX21909 (Macromolecular Resources), and puri- 
fied by reverse-phase HPLC. A peptide N,S,-type Tc-binding cage 
was attached via the amine linker of NX21909N via an NHS-ester reac- 
tion in dry DMSO/S% triethyl amine (TEA). The product of this reaction, 
NX21909N:Hil5, was purified by reverse-phase HPLC. This derivative 
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is significantly less active than its parent, with an inactivation rate con- 
stant of 6 x 1 O6 M-1 min-’ against hNE. The negative controls in all in 
vitro experiments were 30N7 (a pool of oligonucleotides that has 30 
randomized nucleotides between the same 5’ and 3’ PCR primer 
binding sites as the parent library from which NX21909 was selected) 
as the aptamer strand, annealed to a splint oligonucleotide strand 
having a fluorescein attached via a 5’ hexylamine linker, in place of the 
valyl phosphonate moiety of the inhibitor molecules. For in viva experi- 
ments, the DNA oligonucleotide NX303 [301 with a Hi15 cage 
attached at the 5’ end was used as a negative control. This oligonu- 
cleotide binds human, but not rat, L-selectin [30]. Inhibitors and con- 
trols were prepared by mixing equimolar amounts of aptamer and splint 
oligonucleotides in Hank’s balanced saline solution (HBSS) heating to 
65°C and slowly cooling to 37°C. 
Technetium labeling 
For oligonucleotides, 100 yl (10 mCi) of [ ggm Tclsodium pertechnetate 
(Syncor) was added to 100 pl 2 M sodium tartratel0.3 M Tricine 
pH 7.4 with 3 pl 0.5 M tricarboxyethyl phosphine (TCEP, Pierce) as a 
reducing agent, and incubated at 60°C for 10 min. Oligonucleotide 
(0.5-l nmol) was added, along with an additional 1 pl 0.5 M TCEP, 
and incubation at 60°C was continued for 10 min. HBSS/O.Ol% BSA 
(100 ,ul) was added, the reaction was transferred to a Microcon 30 kDa 
MWCO ultrafiltration cartridge and centrifuged to near-dryness. The 
sample was resuspended and recentrifuged three times in 300 pl 
HBSS, then resuspended in 200 pl HBSS. HPLC analysis showed 
that > 950/o of the radioactivity is associated with the oligonucleotide 
(noi shown). Specific activities were typically 0.7-1.5 mCi nmol-’ 
oligonucleotide. 
IgG (rat, Sigma) was labeled by mixing 100 pl of 10 mg ml-’ IgG with 
900 pl HBSS and 150 mg diihiothreitol (DDT), and incubating at room 
temperature for 30 min. Any precipitates were removed by centrifuga- 
tion through a Spin-X 0.45 pm cellulose acetate filter cartridge. DTT 
was removed by centrifugation through Microcon 30 kDa MWCO ultra- 
filtration cartridges, washing with 3 x 400 pl HBSS, and recovering in 
100 pl volume. LGgm Tclsodium pertechnetate was activated as 
described above, then added to the IgG and incubated for 15 min at 
room temperature. Free radiolabel was removed by ultrafiltration as 
described above. Specific activities were 3-4 mCi mg-1 protein. 
Neutrophil preparation 
Blood samples (20 ml) drawn from human volunteers were layered on a 
discontinuous gradient of 12.5 ml each Histopaque 1077 and 
Hi&opaque 11 19 (Sigma) in a 50 ml conical Falcon tube, and cen- 
trifuged in a swinging bucket rotor at 400 g for 30 min at room tempera- 
ture. Neutrophils were drawn from the Histopaque 1077-l 119 interface, 
and any contaminating red blood cells were hypotonically lysed by 30 s 
of vortexing in 3 ml ice-cold water. Lysed cells and Hi&opaque were 
removed by washing cells three times in 20 ml HBSS containing no Caz+ 
or Mg*+. Neutrophils were resuspended in the same buffer, and their 
number and viability were determined by counting in 0.2% Trypan Blue. 
Neutrophils were fixed for binding experiments in 3% paraformalde- 
hyde/0.250/0 glutaraldehyde, following the procedure of [15]. 
Femurs were harvested from 3-5-month-old male Harlan Sprague- 
Dawley rats and placed in CalMg-free HBSS. Within 10 min of har- 
vesting, the ends of the femur were broken off and CalMg-free HBSS 
was squirted through the bone with an 1 &gauge needle until all stringy 
red bone marrow was collected into a 50 ml Falcon tube (45 ml). A 
10 ml syringe (no needle) was used to break up the bone marrow by 
aspiration. The mixture was then strained through a 2360 Falcon cell 
strainer, and cells were pelleted by centrifugation at 700 g for 10 min. 
The pellets were resuspended in 2 ml of E-Lyse (Cardinal Associates), 
vortexed for 1 min and re-pelleted, then resuspended in Ca/Mg-free 
HBSS. The resuspended cells were passed through another 2360 
Falcon cell strainer to remove fat precipitates and then counted via 
Trypan Blue viable staining. The fraction of mature neutroptiils in the 
preparation was 30-40%. 
Inhibition assays 
Elastase activity of 105 neutrophils was determined by the progress 
curve method in a calorimetric assay, using Kmethoxysuccinyl-Ala-Ala- 
Pro-Val-para-nitroanilide as a substrate 1171. LPS (lipopolysaccharide 
from E. co/i) was at 0.1 pg ml-‘; C5a was at 0.1 pg ml-‘; PMA was at 
0.1 pg ml-l; calcium ionophore A23187 was at 0.5 pg ml-‘; IC 
(immune complex) was formed by mixing BSA at 80 pg ml-’ and anti- 
BSA IgG at 800 pg ml-l. 
Cytometry 
Fluorescein-labeled nucleic acids (usually at 30 nM), activator (usually 
PMA at 10 ng ml-‘) and 105 neutrophils were mixed in 0.4 ml HBSS at 
37”C, and allowed to equilibrate for 10 min. Cells were gated and fluo- 
rescence was quantified using a FACScalibur (Becton-Dickinson) fluo- 
rescence-activated cell sorter. 1 O4 events in the neutrophil gate were 
collected for each sample, and fluorescence intensity was calculated 
as the geometric mean of all events within the gate. Data are reported 
as the quotient of intensities in the presence and absence of the fluo- 
rescein-tagged ligands. 
Inflammation imaging 
Male Harlan Sprague-Dawley rats, 250-300 g were anesthetized and 
given intradermal injections of 33 pl anti-BSA (rabbit IgG fraction, 
Cappel) (6 mg ml-‘) or HBSS on the right and left forelimbs, respec- 
tively. BSA (200 PI of 50 mg ml-‘) was given by tail vein intravenous 
injection at the same time. Radiolabeled imaging compounds at 
approximately 0.5 mCi, were administered by tail vein intravenous injec- 
tion 3.5 h after anti-BSA administration. 
Animals were imaged on a Siemens LEM+ gamma camera under con- 
tinuous anesthesia for 40 min, then returned to their cages to recover. 
Additional images were taken at 1, 2, 3 and 4 h after administration of 
the imaging agent. After 4 h, the rats were killed by asphyxiation under 
CO,, and skin samples of approximately 1 cm2 were taken from the 
forelimb injection sites for histochemical analysis. Image presentation 
and analysis were performed using NucLear MAC v2.9 software (Sci- 
entific Imaging, Inc.). An ROI of approximately 1 cm diameter was 
drawn around the injection sites on the forelimb. For the time periods in 
which the rats were under coniinuous anesthesia, and thus immobi- 
lized, this ROI was copied to all frames in the image file, providing a 
consistent size and shape for each measurement. The total number of 
counts in each ROI was evaluated, corrected for decay, and normalized 
to the nominal injected dose. 
In blind experiments, two aliquots each of radiolabeled NX303 and 
NX21909, containing identical amounts of radioactivity, were distrib- 
uted to numbered tubes by Daniel Schneider. The matching of the tube 
numbers with the oligonucleotide identity was not made until the ROI 
analysis was completed. 
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